Clinical Trials
11 results for Bladder Cancer
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
- Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
- Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
- Study ID: NCT01050504
Familial and Atypical Urothelial Cancer Registry
- Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
- Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
- Study ID: NCT00902590
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum
- Condition: Stage IV Bladder Urothelial Carcinoma
- Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
- Study ID: NCT02717156
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
- Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
- Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
- Study ID: NCT03534804
Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"
- Condition: Upper Tract Urothelial Carcinoma
- Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
- Study ID: NCT02969083
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
- Condition: Urothelial Carcinoma
- Intervention: Drug: Sacituzumab govitecan
- Study ID: NCT03547973
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car
- Condition: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
- Intervention: Drug: Durvalumab, Drug: Tremelimumab, Drug: Cisplatin + Gemcitabine, Drug: Carboplatin + Gemcitabine
- Study ID: NCT03682068
Efficacy and Safety of Neoadjuvant Chemotherapy With Dose Dense MVAC Followed by Radical Surgery in Patients With MIBC and Locally Advanced Urothelial Carcinoma of Bladder: Phase II, Single-arm Study
- Condition: Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy
- Intervention: Drug: dose dense MVAC with pegylated GCSF
- Study ID: NCT04047693
An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Locally Advanced and Metastatic Urothelial Carcinoma
- Condition: Urothelial Carcinoma
- Intervention: Drug: ZKAB001 5mg/kg, Drug: ZKAB001 10mg/kg, Drug: ZKAB001 15mg/kg
- Study ID: NCT03676946
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Co
- Condition: Urothelial Carcinoma
- Intervention: Drug: Atezolizumab, Drug: Enfortumab Vedotin, Drug: Niraparib, Drug: Hu5F9-G4, Drug: Isatuximab, Drug: Linagliptin, Drug: Tocilizumab
- Study ID: NCT03869190
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
- Condition: Bladder Cancer, Bladder Cancer, Metastatic
- Intervention: Drug: Atezolizumab
- Study ID: NCT04138628